Gene Therapy Lyfgenia denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for gene therapy lyfgenia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Aetna "Experimental or Investigational" Denial for Lyfgenia — Why It Happens and How to Appeal

Lyfgenia (lovotibeglogene autotemcel) received FDA approval for sickle cell disease. An "experimental or investigational" denial from Aetna means that Aetna's clinical policy review has not yet recognized the therapy as proven — either because the insurer's clinical policy bulletin (CPB) has not been updated to reflect FDA approval, or because Aetna is applying an internal evidentiary standard that goes beyond FDA approval. Both scenarios are legally contestable.

## Why This Denial Is Appealable

Federal and most state laws prohibit insurers from categorically labeling an FDA-approved therapy as experimental solely on the basis of Aetna's own internal evidence standard. The ACA's essential health benefits framework and most state external-review laws specifically authorize independent reviewers to overrule experimental-denial determinations for FDA-approved treatments. Aetna's CPB may lag FDA action — meaning the denial is not a clinical judgment but an administrative gap.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial. Aetna must respond within 30 days (standard) or 72 hours (expedited).
• External review (ACA §2719): Experimental/investigational denials are explicitly subject to external review under ACA §2719. After final internal denial, request an IRO review — generally within approximately 4 months. External reviewers apply clinical standards independent of Aetna's policy.
• ERISA §503: For employer-sponsored plans, federal law guarantees a full-and-fair review of every denial.
• Expedited review: Request in writing if standard timelines jeopardize health.

## Documentation to Gather

1. FDA approval documentation: Print the FDA approval letter and current prescribing label from FDA.gov. These are the foundational documents refuting an experimental designation. 2. Aetna CPB review: Request the specific Clinical Policy Bulletin Aetna applied. Check its effective date against the FDA approval date — a CPB effective before approval may simply be outdated. 3. Guideline organization support: Obtain documentation showing that the relevant national guideline organization (e.g., the applicable hematology/oncology professional society) recognizes this therapy as a standard treatment option for sickle cell disease. 4. Prescriber medical-necessity letter: Your treating hematologist should explicitly state that Lyfgenia is not investigational, is FDA-approved, and is the appropriate treatment for your specific clinical situation. 5. Diagnosis and severity records: Medical records documenting the severity of your sickle cell disease and the inadequacy of prior treatments.

## Criteria-Mapping Structure

| Aetna Experimental Claim | Your Rebuttal Evidence | |---|---| | Lack of proven clinical benefit | FDA approval letter; professional society guidance | | Insufficient evidence standard | IRO applies independent standard — not Aetna's CPB | | CPB does not cover this therapy | Note CPB effective date vs. FDA approval date | | Treatment is investigational | Prescriber attestation; FDA label |

Experimental denials for FDA-approved gene therapies have a strong track record of reversal at the external review stage, where independent physicians — not Aetna's internal reviewers — evaluate the evidence.